Kalbe Farma Tbk PT (KLBF) - Net Assets
Based on the latest financial reports, Kalbe Farma Tbk PT (KLBF) has net assets worth Rp24.19 Trillion IDR (≈ $1.42 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp29.51 Trillion ≈ $1.73 Billion USD) and total liabilities (Rp5.32 Trillion ≈ $311.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Kalbe Farma Tbk PT asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp24.19 Trillion |
| % of Total Assets | 81.98% |
| Annual Growth Rate | 20.06% |
| 5-Year Change | 34.55% |
| 10-Year Change | 124.81% |
| Growth Volatility | 23.42 |
Kalbe Farma Tbk PT - Net Assets Trend (2000–2024)
This chart illustrates how Kalbe Farma Tbk PT's net assets have evolved over time, based on quarterly financial data. Check KLBF tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Kalbe Farma Tbk PT (2000–2024)
The table below shows the annual net assets of Kalbe Farma Tbk PT from 2000 to 2024. For live valuation and market cap data, see market cap of Kalbe Farma Tbk PT.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp24.59 Trillion ≈ $1.44 Billion |
+6.36% |
| 2023-12-31 | Rp23.12 Trillion ≈ $1.35 Billion |
+4.63% |
| 2022-12-31 | Rp22.10 Trillion ≈ $1.29 Billion |
+3.91% |
| 2021-12-31 | Rp21.27 Trillion ≈ $1.25 Billion |
+16.36% |
| 2020-12-31 | Rp18.28 Trillion ≈ $1.07 Billion |
+9.40% |
| 2019-12-31 | Rp16.71 Trillion ≈ $978.88 Million |
+9.23% |
| 2018-12-31 | Rp15.29 Trillion ≈ $896.20 Million |
+10.08% |
| 2017-12-31 | Rp13.89 Trillion ≈ $814.14 Million |
+11.47% |
| 2016-12-31 | Rp12.46 Trillion ≈ $730.33 Million |
+13.95% |
| 2015-12-31 | Rp10.94 Trillion ≈ $640.94 Million |
+11.42% |
| 2014-12-31 | Rp9.82 Trillion ≈ $575.27 Million |
+15.50% |
| 2013-12-31 | Rp8.50 Trillion ≈ $498.06 Million |
+15.31% |
| 2012-12-31 | Rp7.37 Trillion ≈ $431.95 Million |
+13.13% |
| 2011-12-31 | Rp6.52 Trillion ≈ $381.81 Million |
+12.89% |
| 2010-12-31 | Rp5.77 Trillion ≈ $338.21 Million |
+20.48% |
| 2009-12-31 | Rp4.79 Trillion ≈ $280.71 Million |
+10.27% |
| 2008-12-31 | Rp4.34 Trillion ≈ $254.57 Million |
+8.16% |
| 2007-12-31 | Rp4.02 Trillion ≈ $235.36 Million |
+13.34% |
| 2006-12-31 | Rp3.54 Trillion ≈ $207.67 Million |
+26.06% |
| 2005-12-31 | Rp2.81 Trillion ≈ $164.74 Million |
+90.02% |
| 2004-12-31 | Rp1.48 Trillion ≈ $86.69 Million |
+44.55% |
| 2003-12-31 | Rp1.02 Trillion ≈ $59.97 Million |
+57.12% |
| 2002-12-31 | Rp651.41 Billion ≈ $38.17 Million |
+88.28% |
| 2001-12-31 | Rp345.97 Billion ≈ $20.27 Million |
+13.16% |
| 2000-12-31 | Rp305.74 Billion ≈ $17.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kalbe Farma Tbk PT's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2294179129300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp22.94 Trillion | 93.30% |
| Common Stock | Rp468.75 Billion | 1.91% |
| Other Comprehensive Income | Rp869.79 Billion | 3.54% |
| Other Components | Rp310.10 Billion | 1.26% |
| Total Equity | Rp24.59 Trillion | 100.00% |
Kalbe Farma Tbk PT Competitors by Market Cap
The table below lists competitors of Kalbe Farma Tbk PT ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Flight Centre Travel Group Ltd
AU:FLT
|
$1.93 Billion |
|
SIMMTECH Co. Ltd
KQ:222800
|
$1.93 Billion |
|
Shanghai Suochen Information Technology Co. Ltd. A
SHG:688507
|
$1.93 Billion |
|
Anhui Jiangnan Chemical Industry Co Ltd
SHE:002226
|
$1.93 Billion |
|
Sino Horizon Holdings Ltd
TW:2923
|
$1.92 Billion |
|
Vimian Group AB
ST:VIMIAN
|
$1.92 Billion |
|
Forvia SE
PA:FRVIA
|
$1.92 Billion |
|
Shaanxi Huaqin Technology Industry Co. Ltd. A
SHG:688281
|
$1.92 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kalbe Farma Tbk PT's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,120,022,010,215 to 24,590,433,810,000, a change of 1,470,411,799,785 (6.4%).
- Net income of 3,240,636,626,000 contributed positively to equity growth.
- Dividend payments of 1,433,930,309,000 reduced retained earnings.
- Share repurchases of 460,484,944,000 reduced equity.
- New share issuances of 3,088,500,000 increased equity.
- Other comprehensive income increased equity by 44,347,595,044.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp3.24 Trillion | +13.18% |
| Dividends Paid | Rp1.43 Trillion | -5.83% |
| Share Repurchases | Rp460.48 Billion | -1.87% |
| Share Issuances | Rp3.09 Billion | +0.01% |
| Other Comprehensive Income | Rp44.35 Billion | +0.18% |
| Other Changes | Rp76.75 Billion | +0.31% |
| Total Change | Rp- | 6.36% |
Book Value vs Market Value Analysis
This analysis compares Kalbe Farma Tbk PT's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.10x to 1.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | Rp55.36 | Rp725.00 | x |
| 2006-12-31 | Rp69.79 | Rp725.00 | x |
| 2007-12-31 | Rp79.62 | Rp725.00 | x |
| 2008-12-31 | Rp89.07 | Rp725.00 | x |
| 2009-12-31 | Rp100.04 | Rp725.00 | x |
| 2010-12-31 | Rp123.14 | Rp725.00 | x |
| 2011-12-31 | Rp139.01 | Rp725.00 | x |
| 2012-12-31 | Rp157.26 | Rp725.00 | x |
| 2013-12-31 | Rp181.33 | Rp725.00 | x |
| 2014-12-31 | Rp209.44 | Rp725.00 | x |
| 2015-12-31 | Rp233.35 | Rp725.00 | x |
| 2016-12-31 | Rp265.89 | Rp725.00 | x |
| 2017-12-31 | Rp296.41 | Rp725.00 | x |
| 2018-12-31 | Rp326.28 | Rp725.00 | x |
| 2019-12-31 | Rp356.38 | Rp725.00 | x |
| 2020-12-31 | Rp389.90 | Rp725.00 | x |
| 2021-12-31 | Rp453.69 | Rp725.00 | x |
| 2022-12-31 | Rp475.05 | Rp725.00 | x |
| 2023-12-31 | Rp499.83 | Rp725.00 | x |
| 2024-12-31 | Rp532.41 | Rp725.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kalbe Farma Tbk PT utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.18%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.93%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.20x
- Recent ROE (13.18%) is below the historical average (20.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 9.44% | 1.60% | 1.09x | 5.43x | Rp-1.93 Billion |
| 2002 | 40.98% | 10.42% | 1.27x | 3.09x | Rp201.79 Billion |
| 2003 | 31.55% | 11.18% | 1.18x | 2.39x | Rp220.54 Billion |
| 2004 | 25.17% | 10.91% | 1.13x | 2.04x | Rp224.39 Billion |
| 2005 | 25.08% | 12.01% | 1.27x | 1.65x | Rp423.89 Billion |
| 2006 | 21.57% | 12.59% | 1.31x | 1.30x | Rp409.95 Billion |
| 2007 | 20.21% | 11.59% | 1.36x | 1.28x | Rp409.98 Billion |
| 2008 | 19.00% | 10.48% | 1.38x | 1.31x | Rp391.05 Billion |
| 2009 | 21.91% | 11.55% | 1.40x | 1.35x | Rp570.60 Billion |
| 2010 | 23.28% | 13.14% | 1.45x | 1.22x | Rp766.61 Billion |
| 2011 | 23.37% | 13.96% | 1.32x | 1.27x | Rp871.36 Billion |
| 2012 | 23.52% | 12.72% | 1.45x | 1.28x | Rp996.76 Billion |
| 2013 | 22.58% | 12.00% | 1.41x | 1.33x | Rp1.07 Trillion |
| 2014 | 21.03% | 11.89% | 1.40x | 1.27x | Rp1.08 Trillion |
| 2015 | 18.32% | 11.20% | 1.31x | 1.25x | Rp910.41 Billion |
| 2016 | 18.45% | 11.87% | 1.27x | 1.22x | Rp1.05 Trillion |
| 2017 | 17.30% | 11.91% | 1.21x | 1.20x | Rp1.01 Trillion |
| 2018 | 16.07% | 11.66% | 1.16x | 1.19x | Rp927.67 Billion |
| 2019 | 15.01% | 11.08% | 1.12x | 1.21x | Rp836.21 Billion |
| 2020 | 14.96% | 11.83% | 1.02x | 1.23x | Rp905.65 Billion |
| 2021 | 14.97% | 12.12% | 1.02x | 1.21x | Rp1.06 Trillion |
| 2022 | 15.31% | 11.69% | 1.06x | 1.23x | Rp1.17 Trillion |
| 2023 | 11.97% | 9.09% | 1.13x | 1.17x | Rp454.75 Billion |
| 2024 | 13.18% | 9.93% | 1.11x | 1.20x | Rp781.59 Billion |
Industry Comparison
This section compares Kalbe Farma Tbk PT's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more